Giorgio Arnaldi

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5365074/giorgio-arnaldi-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

81 7,051 145 41 h-index g-index citations papers 5.56 4.8 7,907 149 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
145	Mesenchymal Stem Cells Exposed to Persistently High Glucocorticoid Levels Develop Insulin-Resistance and Altered Lipolysis: A Promising Model to Study Cushing's Syndrome <i>Frontiers in Endocrinology</i> , 2022 , 13, 816229	5.7	
144	Osilodrostat oral tablets for adults with Cushing's disease <i>Expert Review of Endocrinology and Metabolism</i> , 2022 , 1-11	4.1	0
143	Acromegaly and male sexual health Reviews in Endocrine and Metabolic Disorders, 2022, 1	10.5	1
142	Copeptin and Stress. Endocrines, 2021, 2, 384-404	0.8	2
141	Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. <i>Frontiers in Endocrinology</i> , 2021 , 12, 595894	5.7	4
140	Ipercortisolismo funzionale e sue possibili conseguenze cliniche. <i>L Endocrinologo</i> , 2021 , 22, 231-237	О	
139	Hypothalamic-Pituitary Diseases and Erectile Dysfunction. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
138	COVID-19 and endocrine and metabolic disorders: critical points and suggestions for a correct therapeutic management from a tertiary endocrine center in Italy. <i>Minerva Endocrinology</i> , 2021 ,	2.5	1
137	Safety and effectiveness of Omnitrope in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 327-337	5.2	1
136	Impact of COVID-19 pandemic on psychophysical stress in patients with adrenal insufficiency: the CORTI-COVID study. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 1075-1084	5.2	9
135	ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2021 , 184, R51-R59	6.5	3
134	Sodium alterations impair the prognosis of hospitalized patients with COVID-19 pneumonia. <i>Endocrine Connections</i> , 2021 , 10, 1344-1351	3.5	2
133	Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. <i>Pituitary</i> , 2020 , 23, 534-542	4.3	3
132	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	13
131	COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 1141-1147	5.2	74
130	Histological Contamination in Clinical Researchfrom Ultrastructure to Stem Cell Biology 2020 , 57-69		
129	Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 683-696	5.2	21

128	Glucocorticoid excess and COVID-19 disease. Reviews in Endocrine and Metabolic Disorders, 2020, 1	10.5	14
127	RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	12
126	The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence". <i>Endocrine</i> , 2019 , 64, 657-672	4	20
125	The diagnostic accuracy of increased late night salivary cortisol for Cushing's syndrome: a real-life prospective study. <i>Journal of Endocrinological Investigation</i> , 2019 , 42, 327-335	5.2	25
124	Gastrolesivit⊡e steroidi: miti e realt□ <i>L Endocrinologo</i> , 2019 , 20, 153-160	О	
123	Somatic PRKACA Mutations: Association With Transition From Pituitary-Dependent to Adrenal-Dependent Cushing Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 565	5 1 -365	7 ¹
122	Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	20
121	Androgens in Cushing's Syndrome. Frontiers of Hormone Research, 2019, 53, 77-91	3.5	7
120	Cushing Syndrome: The Role of MSCs in Wound Healing, Immunosuppression, Comorbidities, and Antioxidant Imbalance. <i>Frontiers in Cell and Developmental Biology</i> , 2019 , 7, 227	5.7	3
119	Personality (at Intrapsychic and Interpersonal Level) Associated With Quality of Life in Patients With Cancer (Lung and Colon). <i>Cancer Control</i> , 2019 , 26, 1073274819880560	2.2	3
118	Ultrasound-based detection of glucocorticoid-induced impairments of muscle mass and structure in Cushing's disease. <i>Journal of Endocrinological Investigation</i> , 2019 , 42, 757-768	5.2	8
117	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes and Endocrinology,the, 2018 , 6, 17-26	18.1	75
116	How to improve effectiveness of pegvisomant treatment in acromegalic patients. <i>Journal of Endocrinological Investigation</i> , 2018 , 41, 575-581	5.2	16
115	Pituitary adenomas, stem cells, and cancer stem cells: what's new?. <i>Journal of Endocrinological Investigation</i> , 2018 , 41, 745-753	5.2	10
114	Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM). <i>Journal of Endocrinological Investigation</i> , 2018 , 41, 3-19	5.2	11
113	The degree of urinary hypercortisolism is not correlated with the severity of cushing's syndrome. <i>Endocrine</i> , 2017 , 55, 564-572	4	24
112	A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype. <i>Endocrine</i> , 2017 , 55, 959-968	4	37
111	Long-term safety and efficacy of Omnitrope in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. <i>Journal of Endocrinological Investigation</i> , 2017 , 40, 669-678	5.2	4

110	Pegvisomant in acromegaly: an update. <i>Journal of Endocrinological Investigation</i> , 2017 , 40, 577-589	5.2	39
109	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , 2017 , 176, 453-461	6.5	39
108	Anoressia nervosa e salute dell ö sso. <i>L Endocrinologo</i> , 2017 , 18, 2-8	O	
107	High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2454-2464	5.6	29
106	Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. <i>Endocrine</i> , 2017 , 57, 156-165	4	30
105	Diagnostic accuracy of increased urinary cortisol/cortisone ratio to differentiate ACTH-dependent Cushing's syndrome. <i>Clinical Endocrinology</i> , 2017 , 87, 500-507	3.4	13
104	Gestione del diabete mellito durante la terapia con pasireotide. <i>L Endocrinologo</i> , 2017 , 18, 13-16	O	
103	Effects of somatostatin and its analogues on progenitor mesenchymal cells isolated from human pituitary adenomas. <i>Pituitary</i> , 2017 , 20, 251-260	4.3	7
102	Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. <i>Endocrine</i> , 2017 , 56, 298-307	4	19
101	A venous thromboembolism risk assessment model for patients with Cushing's syndrome. <i>Endocrine</i> , 2016 , 52, 322-32	4	27
100	ACROSCORE: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease. <i>Clinical Endocrinology</i> , 2016 , 84, 380-5	3.4	18
99	Acromegaly Is More Severe in Patients With AHR or AIP Gene Variants Living in Highly Polluted Areas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 1872-9	5.6	28
98	Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study. <i>Endocrine</i> , 2016 , 54, 762-767	4	23
97	Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome. <i>Pituitary</i> , 2016 , 19, 488-95	4.3	30
96	Update on Hypercortisolism Therapy. Frontiers of Hormone Research, 2016, 46, 87-105	3.5	2
95	A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome. <i>Hormone and Metabolic Research</i> , 2016 , 48, 290-8	3.1	22
94	The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study. <i>Endocrine</i> , 2015 , 50, 154-61	4	10
93	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. Journal of Clinical Endocrinology and Metabolism, 2015 , 100, 3231-44	5.6	79

(2012-2015)

92	treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2015 , 136, 1-10	7.5	41	
91	Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease. <i>Pituitary</i> , 2015 , 18, 60-7	4.3	19	
90	Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations. <i>Pituitary</i> , 2015 , 18, 359-65	4.3	22	
89	Isolation and characterization of progenitor mesenchymal cells in human pituitary tumors. <i>Cancer Gene Therapy</i> , 2015 , 22, 9-16	5.4	25	
88	Bone complications in patients with Cushing's syndrome: looking for clinical, biochemical, and genetic determinants. <i>Osteoporosis International</i> , 2014 , 25, 913-21	5.3	31	
87	Increased frequency of the rs2066853 variant of aryl hydrocarbon receptor gene in patients with acromegaly. <i>Clinical Endocrinology</i> , 2014 , 81, 249-53	3.4	16	
86	MTHFRIC677T polymorphism, folate status and colon cancer risk in acromegalic patients. <i>Pituitary</i> , 2014 , 17, 257-66	4.3	4	
85	Fracture risk assessment before and after resolution of endogenous hypercortisolism: is the FRAXII algorithm useful?. <i>Journal of Endocrinological Investigation</i> , 2014 , 37, 957-65	5.2	6	
84	Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a European multicentric study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E2093-100	5.6	67	
83	Harmful effects of functional hypercortisolism: a working hypothesis. <i>Endocrine</i> , 2014 , 46, 370-86	4	51	
82	Sexual dysfunctions in men affected by autoimmune Addison's disease before and after short-term gluco- and mineralocorticoid replacement therapy. <i>Journal of Sexual Medicine</i> , 2013 , 10, 2036-43	1.1	24	
81	Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 434-48	5.2	62	
80	Adrenal incidentaloma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012 , 26, 405-19	6.5	88	
79	Targeting estrogen receptor-Ireduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E2238-50	5.6	45	
78	Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E165-72	5.6	37	
77	Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2012 , 166, 35-42	6.5	39	
76	Fine-needle aspiration cytology of adrenal masses: a re-assessment with histological confirmation. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 590-4	5.2	8	
75	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 817-23	5.2	48	

74	Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing's disease and pseudo-Cushing state: a comparative study. <i>Clinical Endocrinology</i> , 2011 , 75, 666-7	3 24	32
73	Intrapituitary cytokines in Cushing's disease: do they play a role?. <i>Pituitary</i> , 2011 , 14, 236-41	4.3	10
72	AME position statement on adrenal incidentaloma. European Journal of Endocrinology, 2011, 164, 851-70	% .5	359
71	Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies. <i>European Journal of Endocrinology</i> , 2010 , 162, 361-9	6.5	33
70	Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. <i>European Journal of Endocrinology</i> , 2010 , 163, 369-76	6.5	41
69	Pathophysiology of dyslipidemia in Cushing's syndrome. <i>Neuroendocrinology</i> , 2010 , 92 Suppl 1, 86-90	5.6	111
68	Pasireotide for the treatment of Cushing's disease. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 889-98	5.9	13
67	Coagulopathy in Cushing's syndrome. <i>Neuroendocrinology</i> , 2010 , 92 Suppl 1, 55-9	5.6	43
66	Use of the desmopressin test in the differential diagnosis of pseudo-Cushing state from Cushing's disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 1115-22	5.6	56
65	Primary adrenal hypercortisolism: minimally invasive surgical treatment or medical therapy? A retrospective study with long-term follow-up evaluation. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2010 , 24, 2542-6	5.2	23
64	New treatment guidelines on Cushing's disease. F1000 Medicine Reports, 2009, 1,		7
63	Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 1541-7	5.6	227
62	Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. <i>Journal of Endocrinological Investigation</i> , 2009 , 32, 202-9	5.2	38
61	Approach to the patient with possible Cushing's syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3121-31	5.6	181
60	Human corticotropin releasing hormone test performance in the differential diagnosis between Cushing's disease and pseudo-Cushing state is enhanced by combined ACTH and cortisol analysis. <i>European Journal of Endocrinology</i> , 2009 , 160, 891-8	6.5	28
59	Pituitary-directed medical treatment of Cushing's disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2009 , 4, 263-272	4.1	
58	Different expression of protein kinase A (PKA) regulatory subunits in cortisol-secreting adrenocortical tumors: relationship with cell proliferation. <i>Experimental Cell Research</i> , 2008 , 314, 123-30	4.2	32
57	AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. <i>FASEB Journal</i> , 2008 , 22, 1672-83	0.9	121

(2003-2008)

56	Adrenal morpho-functional alterations in patients with acromegaly. <i>Journal of Endocrinological Investigation</i> , 2008 , 31, 602-6	5.2	14
55	Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 4969-73	5.6	66
54	Adrenal incidentaloma: surgical update. <i>Journal of Endocrinological Investigation</i> , 2007 , 30, 200-4	5.2	25
53	Pegvisomant in acromegaly: why, when, how. <i>Journal of Endocrinological Investigation</i> , 2007 , 30, 693-9	5.2	31
52	Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 2784-92	5.6	108
51	Advances in medical treatment of Cushing's disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2007 , 2, 735-743	4.1	3
50	First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. <i>Journal of Endocrinological Investigation</i> , 2006 , 29, 1017-20	5.2	40
49	Diagnosi della sindrome di Cushing. <i>L Endocrinologo</i> , 2005 , 6, 137-142	O	
48	Expression of growth hormone-releasing hormone receptor splicing variants in human primary adrenocortical tumours. <i>Clinical Endocrinology</i> , 2005 , 62, 533-8	3.4	12
47	Expression profiles for steroidogenic enzymes in adrenocortical disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 5446-55	5.6	96
46	Expression of the novel adrenocorticotropin-responsive gene selective Alzheimer's disease indicator-1 in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 1332-9	5.6	42
45	Italian addison network study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 1598-604	5.6	72
44	High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. <i>Clinical Endocrinology</i> , 2004 , 61, 768-77	3.4	200
43	Cardiovascular risk in Cushing's syndrome. <i>Pituitary</i> , 2004 , 7, 253-6	4.3	79
42	Functional and nonfunctional adrenocortical tumors demonstrate a high responsiveness to low-dose adrenocorticotropin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 1994-8	5.6	11
41	Cyclical Cushing's syndrome in a patient with a bronchial neuroendocrine tumor (typical carcinoid) expressing ghrelin and growth hormone secretagogue receptors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5834-40	5.6	51
40	Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status. <i>Clinical Endocrinology</i> , 2003 , 58, 725-31	3.4	41
39	Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clinical Endocrinology, 2003, 59, 328-38	3.4	33

38	Diagnosis and complications of Cushing's syndrome: a consensus statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5593-602	5.6	1006
37	Mutational analysis of StAR gene in adrenal tumors. <i>International Journal of Cancer</i> , 2002 , 97, 357-60	7.5	1
36	Coenzyme Q10 levels in idiopathic and varicocele-associated asthenozoospermia. <i>Andrologia</i> , 2002 , 34, 107-11	2.4	52
35	Severe hypomagnesaemia-induced hypocalcaemia in a patient with Gitelman's syndrome. <i>Clinical Endocrinology</i> , 2002 , 56, 413-8	3.4	12
34	Bone metabolism and mass in women with Cushing's syndrome and adrenal incidentaloma. <i>Clinical Endocrinology</i> , 2002 , 57, 587-93	3.4	46
33	Self image and quality of life in acromegaly. <i>Pituitary</i> , 2002 , 5, 17-9	4.3	33
32	Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2002 , 146, 303-5	96.5	57
31	Unusual clinical manifestation of pheochromocytoma in a MEN2A patient. <i>Journal of Endocrinological Investigation</i> , 2002 , 25, 53-7	5.2	3
30	Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 5301-6	5.6	95
29	Variable expression of the transcription factors cAMP response element-binding protein and inducible cAMP early repressor in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 5443-9	5.6	19
28	Laurdan fluorescence: a simple method to evaluate sperm plasma membrane alterations. <i>Fertility and Sterility</i> , 2001 , 76, 501-5	4.8	17
27	Hypertension due to renal artery occlusion in a patient with antiphospholipid syndrome. <i>American Journal of Hypertension</i> , 2001 , 14, 62-5	2.3	27
26	Body Composition and Metabolic Features in Women with Adrenal Incidentaloma or Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 5301-5306	5.6	72
25	Effects of long-term treatment with human pure follicle-stimulating hormone on semen parameters and sperm-cell ultrastructure in idiopathic oligoteratoasthenozoospermia. <i>Andrologia</i> , 2000 , 32, 155-61	2.4	14
24	Adrenal incidentaloma. Brazilian Journal of Medical and Biological Research, 2000, 33, 1177-89	2.8	37
23	Telomerase activity is significantly enhanced in malignant adrenocortical tumors in comparison to benign adrenocortical adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 468-70	5.6	24
22	A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 637-44	5.6	633
21	Transforming growth factor beta1: implications in adrenocortical tumorigenesis. <i>Endocrine Research</i> , 2000 , 26, 905-10	1.9	4

20	Masse surrenaliche incidentali: protocollo diagnostico. L Endocrinologo, 2000 , 1, 55-62	О	
19	Management approaches to adrenal incidentalomas. A view from Ancona, Italy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2000 , 29, 107-25, ix	5.5	55
18	A Survey on Adrenal Incidentaloma in Italy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 637-644	5.6	479
17	Investigation protocol: adrenal enlargement. Clinical Endocrinology, 1999, 50, 141-6	3.4	22
16	Vasopressin receptors modulate the pharmacological phenotypes of Cushing's syndrome. <i>Endocrine Research</i> , 1998 , 24, 807-16	1.9	12
15	Laparoscopic adrenalectomy: a report on 50 operations. <i>European Journal of Endocrinology</i> , 1998 , 138, 548-53	6.5	43
14	Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 4207-11	5.6	26
13	Variable expression of the V1 vasopressin receptor modulates the phenotypic response of steroid-secreting adrenocortical tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 20	2 5 -35	53
12	ACTH receptor mRNA in human adrenocortical tumors: overexpression in aldosteronomas. <i>Endocrine Research</i> , 1998 , 24, 845-9	1.9	30
11	Adrenocorticotropin and Cortisol Hyperresponsiveness to Hexarelin in Patients with Cushing's Disease Bearing a Pituitary Microadenoma, But Not in Those with Macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 4207-4211	5.6	19
10	Variable Expression of the V1 Vasopressin Receptor Modulates the Phenotypic Response of Steroid-Secreting Adrenocortical Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2029-2035	5.6	52
9	Adrenal incidentaloma: an overview of hormonal data from the National Italian Study Group. <i>Hormone Research</i> , 1997 , 47, 284-9		131
8	Angiotensin II Receptors in Cortical and Medullary Adrenal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 865-869	5.6	6
7	Enhanced expression of transforming growth factor beta1 in rat thyroid hyperplasia is thyrotropin induced and time dependent. <i>European Journal of Endocrinology</i> , 1996 , 134, 373-8	6.5	20
6	Apparent mineralocorticoid excess type II. <i>Steroids</i> , 1994 , 59, 80-3	2.8	39
5	Decreased expression of insulin-sensitive glucose transporter mRNA (GLUT-4) in adipose tissue of non-insulin-dependent diabetic and obese patients: evaluation by a simplified quantitative PCR assay. <i>Journal of Endocrinological Investigation</i> , 1994 , 17, 709-15	5.2	15
4	Transforming growth factor-beta 1 is more expressed in thyroid follicular adenoma than in normal tissue. <i>Journal of Endocrinological Investigation</i> , 1994 , 17, 335-40	5.2	18
3	A novel endothelial tyrosine kinase cDNA homologous to platelet-derived growth factor receptor cDNA. <i>Biochemical and Biophysical Research Communications</i> , 1992 , 186, 706-14	3.4	18

Hypertension-induced changes of platelet-derived growth factor receptor expression in rat aorta and heart. *Hypertension*, **1991**, 17, 888-95

8.5 62

Effects of hypertension and aging on platelet-derived growth factor and platelet-derived growth factor receptor expression in rat aorta and heart. *Hypertension*, **1991**, 18, III93-9

8.5 36